A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine.
In a randomized clinical trial, researchers tested low-dose methotrexate, a drug often prescribed for rheumatoid arthritis, in 215 patients with inflammatory knee osteoarthritis and effusion-synovitis. The trial was conducted across 11 sites in China between 2019 and 2023, with more than 80% of enrolled participants completing the study.
Over the 52-week trial, the study showed there was no statistically significant difference in pain or joint swelling between the methotrexate and a placebo.
Specifically, researchers found no difference in knee pain scores and in the area of effusion-synovitis, suggesting the drug did not provide meaningful symptom relief or disease modification.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
